Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
Saved in:
| Title: | Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. |
|---|---|
| Authors: | Demarest JF; Clear Creek Bio, Cambridge, MA, USA., Kienle M; Clear Creek Bio, Cambridge, MA, USA., Boytz R; NEIDL, Boston University, Boston, MA, USA., Ayres M; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA., Kim EJ; University of Louisville, Louisville, KY, USA., Patten JJ; NEIDL, Boston University, Boston, MA, USA., Chung D; University of Louisville, Louisville, KY, USA., Gandhi V; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA., Davey RA; NEIDL, Boston University, Boston, MA, USA., Sykes DB; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA., Shohdy N; Clear Creek Bio, Cambridge, MA, USA., Pottage JC Jr; Clear Creek Bio, Cambridge, MA, USA., Kumar VS; Clear Creek Bio, Cambridge, MA, USA. Electronic address: brq@clearcreekbio.com. |
| Source: | Antiviral research [Antiviral Res] 2022 Oct; Vol. 206, pp. 105403. Date of Electronic Publication: 2022 Aug 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9096 (Electronic) Linking ISSN: 01663542 NLM ISO Abbreviation: Antiviral Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36041646 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Demarest+JF%22">Demarest JF</searchLink>; Clear Creek Bio, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kienle+M%22">Kienle M</searchLink>; Clear Creek Bio, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Boytz+R%22">Boytz R</searchLink>; NEIDL, Boston University, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ayres+M%22">Ayres M</searchLink>; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kim+EJ%22">Kim EJ</searchLink>; University of Louisville, Louisville, KY, USA.<br /><searchLink fieldCode="AU" term="%22Patten+JJ%22">Patten JJ</searchLink>; NEIDL, Boston University, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Chung+D%22">Chung D</searchLink>; University of Louisville, Louisville, KY, USA.<br /><searchLink fieldCode="AU" term="%22Gandhi+V%22">Gandhi V</searchLink>; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Davey+RA%22">Davey RA</searchLink>; NEIDL, Boston University, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sykes+DB%22">Sykes DB</searchLink>; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA.<br /><searchLink fieldCode="AU" term="%22Shohdy+N%22">Shohdy N</searchLink>; Clear Creek Bio, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pottage+JC+Jr%22">Pottage JC Jr</searchLink>; Clear Creek Bio, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kumar+VS%22">Kumar VS</searchLink>; Clear Creek Bio, Cambridge, MA, USA. Electronic address: brq@clearcreekbio.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228109699%22">Antiviral research</searchLink> [Antiviral Res] 2022 Oct; Vol. 206, pp. 105403. <i>Date of Electronic Publication: </i>2022 Aug 28. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8109699 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-9096 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201663542%22">01663542 </searchLink><i>NLM ISO Abbreviation: </i>Antiviral Res <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36041646 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.antiviral.2022.105403 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 105403 Titles: – TitleFull: Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Demarest JF – PersonEntity: Name: NameFull: Kienle M – PersonEntity: Name: NameFull: Boytz R – PersonEntity: Name: NameFull: Ayres M – PersonEntity: Name: NameFull: Kim EJ – PersonEntity: Name: NameFull: Patten JJ – PersonEntity: Name: NameFull: Chung D – PersonEntity: Name: NameFull: Gandhi V – PersonEntity: Name: NameFull: Davey RA – PersonEntity: Name: NameFull: Sykes DB – PersonEntity: Name: NameFull: Shohdy N – PersonEntity: Name: NameFull: Pottage JC Jr – PersonEntity: Name: NameFull: Kumar VS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2022 Oct Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1872-9096 Numbering: – Type: volume Value: 206 Titles: – TitleFull: Antiviral research Type: main |
| ResultId | 1 |
